Lonafarnib

(Zokinvy®)

Lonafarnib

Latest News

loading GIF

Drug updated on 6/2/2024

Dosage FormCapsule (oral; 50 mg, 75 mg)
Drug ClassFarnesyltransferase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in patients 12 months of age and older with a body surface area of 0.39 m² and above to reduce risk of mortality in Hutchinson-Gilford progeria syndrome.
  • Indicated in patients 12 months of age and older with a body surface area of 0.39 m² and above for treatment of processing-deficient progeroid laminopathies with heterozygous LMNA mutation with progerin-like protein accumulation.
  • Indicated in patients 12 months of age and older with a body surface area of 0.39 m² and above for treatment of processing-deficient progeroid laminopathies with homozygous or compound heterozygous ZMPSTE24 mutations.

Product Monograph / Prescribing Information

Document TitleYearSource
Zokinvy (lonafarnib) Prescribing Information.2020Eiger BioPharmaceuticals, Inc., Palo Alto, CA

Randomized Controlled Trials